Drug intelligence / Profile preview

ALY-281

Development stage: Preclinical
Lead developer: Alys Pharmaceuticals
Modality: Small Molecules

Overview

ALY-281 is a small molecule therapeutic candidate being developed by Alys Pharmaceuticals for the treatment of Hidradenitis Suppurativa (HS). The program was originally part of the pipeline at Granular Therapeutics, which became a subsidiary of Alys Pharmaceuticals following a multi-company merger in early 2024. Hidradenitis Suppurativa is a chronic, inflammatory skin condition characterized by painful nodules, abscesses, and scarring, for which there are limited effective treatments. ALY-281 is currently in the preclinical stage of development, and while its specific molecular target has not been publicly disclosed, it is part of a broader portfolio focused on immune-inflammatory skin diseases.

Beyond the preview

Go deeper on ALY-281.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALY-281.

Explore the full profile